Warrant Extension TORONTO, ON / ACCESSWIRE / February 4, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the "Exchange") to extend the expiry date of 5,702,314.00 outstanding common share purchase warrants (the "Warrants") to January 31, 2023. The Warrants consist of certain of the Company's Warrants that are currently due to expire in 2022.
The Warrants were originally issued pursuant to non-brokered private placements and debenture conversions. None of the Warrants to be extended are held, directly or indirectly, by any insiders of the Company.
https://www.accesswire.com/687263/StageZero-Life-Sciences-Announces-Warrant-Extension